SCHEMBL16396268

SCHEMBL16396268

CC(C)(C)OC(=O)Cc1ccccc1OCc1cc(Cl)cc(N2CCCCC2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ PTGER1 P34995 3/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 2/20 0.39
▸ MRGPRX4 Q96LA9 2/20 0.38
▸ PSMD14 O00487 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ MMP2 P08253 1/20 0.38
▸ KCNQ2 O43526 3/20 0.38
▸ GAA P10253 1/20 0.37
▸ GFER P55789 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ MAPT P10636 2/20 0.37
▸ SMN1; SMN2 Q16637 2/20 0.37
▸ LRRK2 Q5S007 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ LMNA P02545 1/20 0.37
▸ MAPK1 P28482 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17764342 0.86 CFD (0.47) MEN1KMT2APTGER1HPGDMRGPRX4
SCHEMBL16397377 0.81 CFD (0.43) PTGER1CYP2C9GAAMAPTSMN1; SMN2
SCHEMBL16410429 0.80 MEN1 (0.43) MEN1KMT2APTGER1CYP2C9PSMD14
SCHEMBL16397192 0.79 MTNR1A (0.38) MEN1KMT2APTGER1CYP2C9GAA
SCHEMBL16396265 0.79 MTNR1A (0.40) PTGER1CYP2C9
SCHEMBL16396476 0.79 MTNR1A (0.40) PTGER1CYP2C9GAAMAPTSMN1; SMN2
SCHEMBL16396881 0.79 MTNR1A (0.40) PTGER1CYP2C9L3MBTL1
SCHEMBL16397748 0.78 CFD (0.38) PTGER1CYP2C9GAAMAPTSMN1; SMN2
SCHEMBL16410551 0.77 CFD (0.38) PTGER1CYP2C9GAAMAPTSMN1; SMN2
SCHEMBL16396642 0.77 PTGER1 (0.36) PTGER1CYP2C9HPGDGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof NOVARTIS AG (CH) 2016-05-26 — — US disclosed
EP-3022182-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF Novartis AG (CH) 2016-05-25 — — EP disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed
WO-2015009977-A1 AMINOMETHYL-BIARYL DERIVATIVES AS COMPLEMENT FACTOR D INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2015-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145247-A1 Aminomethyl-Biaryl Derivatives Complement Factor D inhibitors and uses thereof CFD, CFH, CFB MEN1 689/4885KMT2A 1918/4885PTGER1 1777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback